NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has signed a credentialing agreement with Three Rivers Provider Network, which will offer the firm's Cancer Origin Test to members of the preferred provider organization.
Three Rivers, based in Chula Vista, Calif., provides health benefits to more than 10 million members nationwide. It also has more than 600,000 providers, 5,000 hospitals, and 70,000 ancillary facilities in its network.
The Rosetta Cancer Origin Test is a microRNA-based molecular diagnostic that is used to identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary.
The agreement with Three Rivers is the second credentialing agreement the firm has signed with a PPO. Last month, Rosetta said that it had inked a credentialing agreement with managed care firm Prime Health Services to cover its miRview mets2 test, which it has since rebranded as the Rosetta Cancer Origin Test.
"Together with Medicare reimbursement, the total number of covered lives and for which the Rosetta Cancer Origin Test could be adjudicated as 'in-network' now exceeds 61 million, which means that one in five Americans are covered for the Rosetta Cancer Origin Test," Kenneth Berlin, president and CEO of Rosetta Genomics, said in a statement. "We continue to pursue additional agreements with other PPOs as they provide faster payment while maintaining acceptable levels of reimbursement, and also reduce costs incurred through appealing denials. This has become increasingly important to our company as we continue to see a growing number of samples being processed and billed by our CLIA lab."
In Friday morning trade on the Nasdaq, shares of Rosetta were up 9 percent at $4.24.